Archive: Company News
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
— Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patients
— Pipeline molecule to treat T cell mediated autoimmune diseases
selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T cell mediated autoimmune diseases, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will be held Thursday, January 11, 2024, 08:00 AM – 08:25 AM PST at Golden Gate (32nd Floor), The Westin.
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced the first patient dosing in the clinical Phase I/II trial evaluating FB849 in patients with advanced solid tumors.
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
— HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptor
— Designed to target myeloid, NK and T cells and to be precisely directed to tumor sites
— Potent in vitro anti-tumor efficacy demonstrated
ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.